A Snapshot of Five Contenders to Combat Infectious Diseases in the Post-Pandemic Landscape
Infectious disease is the focus of the biopharma track at INVEST Pitch Perfect May 20-21 in Chicago. Register today!
Healthcare Startups are Running Out of Time
The deadline to apply for the INVEST Pitch Perfect Contest is January 24! In addition to a business profile, Pitch Perfect winners also receive a $20,000 branding advertising package from MedCity News.
presented by
The Top 6 Best Analytics Tools for Health Care Revenue in 2025
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
Gates Foundation Joins Radiant Bio’s $35M Round for Antibody Drugs With ‘Better Grip’
Radiant Biotherapeutics’ Multabodies are antibodies engineered to offer better binding strength to their targets. The preclinical startup’s lead program goes after a cancer immunotherapy target being pursued by several biotech companies already in early clinical development.
FDA Approves Emergent BioSolutions Vaccine as New Tool in Fight Against Mpox
Emergent BioSolutions’ smallpox vaccine, ACAM2000, now has an additional FDA approval covering mpox. It’s one of two FDA-approved mpox vaccines, joining Jynneos from Bavarian Nordic.
GSK Pays CureVac €400M to Pick Up Clinical-Stage mRNA Vaccines for Infectious Diseases
GSK is taking over development of an avian influenza vaccine candidate as a bird flu outbreak continues in U.S. dairy cows. Meanwhile, CureVac is restructuring and returning its attention to cancer vaccines, which was the initial focus of the mRNA company.
Bavarian Nordic Hones Infectious Disease Focus by Dropping Cancer Vaccine R&D
Bavarian Nordic will concentrate on its portfolio and pipeline of infectious diseases vaccines, including top seller Jynneos, approved for mpox and smallpox. The company only had one clinical-stage cancer vaccine program.
presented by
The Top-Rated Orthopedic Surgery Centers in the Houston Area and Beyond
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.
NIH Marburg Vaccine Posts Encouraging Results in First-in-Human Study
Marburg virus has no FDA-approved vaccines or therapies, but a vaccine candidate from the National Institutes of Health now has encouraging results from a U.S. clinical trial. Next steps include tests in more countries including Ghana, where a Marburg outbreak was declared last summer.
GSK’s Phase 3 results make it a top contender in chase for first RSV vaccine
Respiratory syncytial virus has no approved vaccines anywhere in the world, but the chase to bring the first one to the market is heating up. GSK reported Phase 3 data that position it for regulatory submissions the pharma giant is planning for later this year. Pfizer is also on track to seek regulatory approvals for its RSV vaccine candidate.
FDA approves RedHill’s drug for cancer-causing H. pylori bacterial infections
Shares of the company were up more than 13 percent on the Tel Aviv Stock Exchange following the approval of Talicia, meant to address the growing issue of the bacteria's resistance to antibiotics. H. pylori is a major cause of gastric cancer.
BOA Biomedical seeks to address antibiotic resistance and sepsis
Harvard’s Wyss Institute and VC firm Miraki Innovation have created a joint venture BOA Biomedical, which is developing a device that could diagnose and treat infectious diseases.
Navigating The Right Steps For Your Healthcare Startup
This webinar will explore how a banking platform approach could be the resource for your company.
UPMC creates telemedicine company to address shortage of infectious disease specialists
The company, which is called Infectious Disease (ID) Connect, aims to virtually connect UPMC infectious disease specialists to other hospitals.
Karius’ NGS test for infections shows high sensitivity in pilot study
The study, conducted with St. Jude Children's Research Hospital, showed a 78 percent predictive sensitivity two days before the onset of infection.
MeMed gets $9.2M to develop tools to distinguish between bacterial and viral infections
The ultimate goal of MeMed is to right-size antibiotic use. The team is working on a second-generation platform that gets results in minutes and that anyone can use.
Sherwin-Williams debuts Paint Shield to prevent spread of bacteria on surfaces
Many infectious diseases could now be tackled by Sherwin Williams' new paint designed to kill certain bacteria for up to four years.
‘Microbial cloud’ in breath could identify you, much like skin or hair
It's possible that the air we are breathing could be identifying, much like a fingerprint or DNA from our hair.